Doxazosin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (6)Enzymes (2)Carriers (1)Transporters (1)

Targets (6)Enzymes (2)Carriers (1)Transporters (1)Biointeractions (9)

Identification

Name

Doxazosin

Accession Number

DB00590 (APRD00474)

Type

Small Molecule

Groups

Approved

Description

Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α₁-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α₁-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin

1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin

Doxazosina

Doxazosine

Doxazosinum

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Doxazosin mesylate	86P6PQK0MU	77883-43-3	VJECBOKJABCYMF-UHFFFAOYSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Cardura	Tablet	8 mg/1	Oral	Roerig	1990-11-02	Not applicable	US
Cardura	Tablet	4 mg/1	Oral	Roerig	1990-11-02	Not applicable	US
Cardura	Tablet	1 mg/1	Oral	Roerig	1990-11-02	Not applicable	US
Cardura	Tablet	2 mg/1	Oral	Roerig	1990-11-02	Not applicable	US
Cardura XL	Tablet, multilayer, extended release	4 mg/1	Oral	Roerig	2005-02-22	Not applicable	US
Cardura XL	Tablet, multilayer, extended release	8 mg/1	Oral	Roerig	2005-02-22	Not applicable	US
Cardura-1 Tab 1mg	Tablet	1 mg	Oral	Pfizer	1992-12-31	Not applicable	Canada
Cardura-2 Tab 2mg	Tablet	2 mg	Oral	Pfizer	1992-12-31	Not applicable	Canada
Cardura-4 Tab 4mg	Tablet	4 mg	Oral	Pfizer	1992-12-31	Not applicable	Canada
Dom-doxazosin	Tablet	1 mg	Oral	Dominion Pharmacal	2004-05-26	Not applicable	Canada
Dom-doxazosin	Tablet	2 mg	Oral	Dominion Pharmacal	2004-05-26	Not applicable	Canada
Dom-doxazosin	Tablet	4 mg	Oral	Dominion Pharmacal	2004-05-26	Not applicable	Canada
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Greenstone, Llc	2014-07-07	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Greenstone, Llc	2014-07-07	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Remedy Repack	2017-04-04	Not applicable	US
Doxazosin Mesylate	Tablet	8 mg/1	Oral	Greenstone, Llc	2014-07-07	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Remedy Repack	2015-11-12	Not applicable	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	Greenstone, Llc	2014-07-07	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Remedy Repack	2016-01-14	2017-04-14	US
Doxazosin-1	Tablet	1 mg	Oral	Pro Doc Limitee	2000-05-10	Not applicable	Canada
Doxazosin-2	Tablet	2 mg	Oral	Pro Doc Limitee	2000-05-10	Not applicable	Canada
Doxazosin-4	Tablet	4 mg	Oral	Pro Doc Limitee	2000-05-10	Not applicable	Canada
Mylan-doxazosin	Tablet	4 mg	Oral	Mylan Pharmaceuticals	1999-07-16	2017-01-09	Canada
Mylan-doxazosin	Tablet	1 mg	Oral	Mylan Pharmaceuticals	1999-07-16	2017-01-09	Canada
Mylan-doxazosin	Tablet	2 mg	Oral	Mylan Pharmaceuticals	1999-07-16	2017-01-09	Canada
PMS-doxazosin	Tablet	1 mg	Oral	Pharmascience Inc	2001-10-01	Not applicable	Canada
PMS-doxazosin	Tablet	2 mg	Oral	Pharmascience Inc	2001-10-01	Not applicable	Canada
PMS-doxazosin	Tablet	4 mg	Oral	Pharmascience Inc	2001-10-01	Not applicable	Canada
Ratio-doxazosin	Tablet	4 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2001-02-13	2006-08-04	Canada
Ratio-doxazosin	Tablet	1 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2001-02-13	2006-08-04	Canada
Ratio-doxazosin	Tablet	2 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2001-02-13	2006-08-04	Canada
Teva-doxazosin	Tablet	4 mg	Oral	Teva	2000-09-01	Not applicable	Canada
Teva-doxazosin	Tablet	1 mg	Oral	Teva	2000-09-01	Not applicable	Canada
Teva-doxazosin	Tablet	2 mg	Oral	Teva	2000-09-01	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-doxazosin	Tablet	4 mg	Oral	Apotex Corporation	1999-07-22	Not applicable	Canada
Apo-doxazosin	Tablet	1 mg	Oral	Apotex Corporation	1999-07-22	Not applicable	Canada
Apo-doxazosin	Tablet	2 mg	Oral	Apotex Corporation	1999-07-22	Not applicable	Canada
Doxazosin	Tablet	2 mg/1	Oral	Mylan Pharmaceuticals	2000-10-20	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Cardinal Health	2011-08-18	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Remedy Repack	2013-05-13	2016-04-05	US
Doxazosin	Tablet	1 mg/1	Oral	A S Medication Solutions	2011-07-14	2017-06-20	US
Doxazosin	Tablet	2 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-10-27	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2000-10-20	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Legacy Pharmaceutical Packaging	2011-07-14	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Teva	2014-09-09	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	A S Medication Solutions	2011-07-14	2017-06-20	US
Doxazosin	Tablet	2 mg/1	Oral	Accord Healthcare Limited	2015-03-24	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	A S Medication Solutions	2015-04-22	2017-06-20	US
Doxazosin	Tablet	8 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-04-22	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Accord Healthcare Limited	2017-06-14	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2000-10-19	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Aidarex Pharmaceuticals LLC	2011-10-27	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	A S Medication Solutions	2000-10-20	2017-06-20	US
Doxazosin	Tablet	8 mg/1	Oral	Unit Dose Services	2015-04-22	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Legacy Pharmaceutical Packaging	2011-07-14	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Remedy Repack	2014-01-22	2017-04-29	US
Doxazosin	Tablet	4 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2000-10-19	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Mylan Institutional	2001-01-01	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Physicians Total Care, Inc.	2003-05-28	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Av Kare, Inc.	2015-04-09	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-04-21	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Teva	2000-10-20	2015-10-31	US
Doxazosin	Tablet	1 mg/1	Oral	Major	2011-07-14	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Apotex Corporation	2011-07-14	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Remedy Repack	2013-05-23	2016-12-10	US
Doxazosin	Tablet	8 mg/1	Oral	A S Medication Solutions	2011-07-14	2017-06-20	US
Doxazosin	Tablet	1 mg/1	Oral	A S Medication Solutions	2015-03-04	2017-06-20	US
Doxazosin	Tablet	4 mg/1	Oral	Amerincan Health Packaging	2014-09-22	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Mylan Pharmaceuticals	2000-10-20	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Remedy Repack	2015-11-02	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Unit Dose Services	2000-10-20	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	bryant ranch prepack	2011-03-08	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Major	2011-07-14	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Apotex Corporation	2011-07-14	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	A S Medication Solutions	2015-03-04	2017-06-20	US
Doxazosin	Tablet	2 mg/1	Oral	A S Medication Solutions	2015-04-22	2017-06-20	US
Doxazosin	Tablet	1 mg/1	Oral	Clinical Solutions Wholsesale	2011-07-14	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	bryant ranch prepack	2000-10-20	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Remedy Repack	2013-02-25	2016-03-31	US
Doxazosin	Tablet	2 mg/1	Oral	Cardinal Health	2000-10-20	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2000-10-20	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2000-10-19	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Unit Dose Services	2000-10-20	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2000-10-20	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-05-02	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2011-03-08	2017-02-22	US
Doxazosin	Tablet	4 mg/1	Oral	Mylan Pharmaceuticals	2000-10-20	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Cardinal Health	2011-08-18	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	A S Medication Solutions	2011-07-14	2017-06-20	US
Doxazosin	Tablet	2 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-06-24	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Amerincan Health Packaging	2014-09-22	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2000-10-20	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Teva	2014-08-06	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2000-10-20	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Accord Healthcare Limited	2015-03-24	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	A S Medication Solutions	2015-04-22	2017-06-20	US
Doxazosin	Tablet	2 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-04-22	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2000-10-20	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Remedy Repack	2015-11-23	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Mylan Institutional	2001-01-01	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Physicians Total Care, Inc.	2003-05-28	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Av Kare, Inc.	2015-04-09	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Remedy Repack	2014-12-01	2017-02-28	US
Doxazosin	Tablet	2 mg/1	Oral	Major	2011-07-14	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Apotex Corporation	2011-07-14	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	A S Medication Solutions	2015-04-22	2017-06-20	US
Doxazosin	Tablet	4 mg/1	Oral	Remedy Repack	2013-03-14	2016-10-13	US
Doxazosin	Tablet	4 mg/1	Oral	Cardinal Health	2000-10-20	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2000-10-20	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	bryant ranch prepack	2011-03-08	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Teva	2014-12-05	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Accord Healthcare Limited	2015-03-04	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	A S Medication Solutions	2011-07-14	2017-06-20	US
Doxazosin	Tablet	4 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-04-22	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Clinical Solutions Wholsesale	2011-07-14	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-07-14	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Legacy Pharmaceutical Packaging	2011-07-14	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2011-07-14	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2000-10-19	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Unit Dose Services	2000-10-20	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Physicians Total Care, Inc.	2003-04-03	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Rebel Distributors	2011-03-08	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	St. Marys Medical Park Pharmacy	2014-04-21	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2011-03-08	2017-02-22	US
Doxazosin	Tablet	8 mg/1	Oral	Mylan Pharmaceuticals	2000-10-20	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Cardinal Health	2011-08-18	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Stat Rx USA	2009-10-27	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	A S Medication Solutions	2011-07-14	2017-06-20	US
Doxazosin	Tablet	2 mg/1	Oral	Unit Dose Services	2015-04-22	Not applicable	US
Doxazosin	Tablet	2 mg/1	Oral	Amerincan Health Packaging	2014-09-22	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Teva	2014-08-06	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Accord Healthcare Limited	2015-03-24	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Unit Dose Services	2015-04-22	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Apotex Corporation	2011-07-14	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	A S Medication Solutions	2015-04-22	2017-06-20	US
Doxazosin	Tablet	2 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2015-04-22	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Mylan Institutional	2001-01-01	Not applicable	US
Doxazosin	Tablet	1 mg/1	Oral	Physicians Total Care, Inc.	2003-08-14	Not applicable	US
Doxazosin	Tablet	8 mg/1	Oral	Av Kare, Inc.	2015-04-09	Not applicable	US
Doxazosin	Tablet	4 mg/1	Oral	Remedy Repack	2015-06-01	2017-04-14	US
Doxazosin	Tablet	4 mg/1	Oral	Major	2011-07-14	Not applicable	US
Doxazosin Mesylate	Tablet	8 mg/1	Oral	Golden State Medical Supply	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Dispensing Solutions, Inc.	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-12-10	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Remedy Repack	2010-07-29	2017-03-09	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	A S Medication Solutions	2004-06-10	2017-06-20	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	DAVA Pharmaceuticals, Inc.	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	Remedy Repack	2017-01-27	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Remedy Repack	2011-11-16	2016-11-03	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Golden State Medical Supply	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Remedy Repack	2011-06-06	2017-04-14	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	Av Pak	2017-01-25	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Major	2010-04-28	Not applicable	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	State of Florida DOH Central Pharmacy	2014-11-01	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Blenheim Pharmacal, Inc.	2013-12-10	Not applicable	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	Remedy Repack	2014-05-27	2016-12-16	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Golden State Medical Supply	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Remedy Repack	2011-05-09	2017-04-14	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	DAVA Pharmaceuticals, Inc.	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	Av Pak	2017-01-25	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Major	2010-05-06	Not applicable	US
Doxazosin Mesylate	Tablet	8 mg/1	Oral	A S Medication Solutions	2004-06-10	2017-06-20	US
Doxazosin Mesylate	Tablet	8 mg/1	Oral	Major	2010-04-28	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	DAVA Pharmaceuticals, Inc.	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	8 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	Golden State Medical Supply	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	Remedy Repack	2011-03-31	2017-04-14	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Av Pak	2017-01-25	Not applicable	US
Doxazosin Mesylate	Tablet	1 mg/1	Oral	Remedy Repack	2015-04-14	Not applicable	US
Doxazosin Mesylate	Tablet	8 mg/1	Oral	DAVA Pharmaceuticals, Inc.	2004-06-10	Not applicable	US
Doxazosin Mesylate	Tablet	4 mg/1	Oral	A S Medication Solutions	2004-06-10	2017-06-20	US
Doxazosin Mesylate	Tablet	8 mg/1	Oral	Av Pak	2017-01-25	Not applicable	US
Doxazosin Mesylate	Tablet	2 mg/1	Oral	Major	2010-04-28	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Alfadil	Pfizer (Sweden)
Cardenalin	Pfizer (Japan; discontinued)
Cardular	Pfizer (Germany)
Cardura-1	Pfizer (Canada)
Cardura-2	Pfizer (Canada)
Cardura-4	Pfizer (Canada)
Carduran	Pfizer (Brazil, Denmark, Norway, Spain)
Diblocin	AstraZeneca (Germany)
Normothen	Bioindustria (Italy)
Supressin	Pfizer (Austria)

Brand mixtures

Name	Labeller	Ingredients
Cardura-1,2,and 4	Astra Zeneca	Doxazosin Doxazosin Doxazosin

Categories

UNII

NW1291F1W8

CAS number

74191-85-8

Weight

Average: 451.4751
Monoisotopic: 451.185568935

Chemical Formula

C₂₃H₂₅N₅O₅

InChI Key

RUZYUOTYCVRMRZ-UHFFFAOYSA-N

InChI

InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)

IUPAC Name

2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine

SMILES

COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1

Pharmacology

Indication

For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.

Structured Indications

Pharmacodynamics

Doxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1a adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity.

Mechanism of action

Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Alpha-1A adrenergic receptor	Protein	yes	antagonist	Human	P35348	details
Alpha-1B adrenergic receptor	Protein	yes	antagonist	Human	P35368	details
Alpha-1D adrenergic receptor	Protein	yes	antagonist	Human	P25100	details
Potassium voltage-gated channel subfamily H member 2	Protein	unknown	inhibitor	Human	Q12809	details
Potassium voltage-gated channel subfamily H member 6	Protein	unknown	inhibitor	Human	Q9H252	details
Potassium voltage-gated channel subfamily H member 7	Protein	unknown	inhibitor	Human	Q9NS40	details

Absorption

65%

Volume of distribution

Not Available

Protein binding

98%

Metabolism

Hepatic.

Route of elimination

On average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.

Half life

22 hours

Clearance

Not Available

Toxicity

Symptoms of overdose include hypotension. Oral LD₅₀ is greater than 1000 mg/kg in mice and rats.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Doxazosin.	Experimental
Abiraterone	The serum concentration of Doxazosin can be increased when it is combined with Abiraterone.	Approved
Acebutolol	Acebutolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Doxazosin.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Acetazolamide.	Approved, Vet Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Adrafinil	Doxazosin may decrease the vasoconstricting activities of Adrafinil.	Withdrawn
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Doxazosin.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Doxazosin.	Experimental
Alfuzosin	Alfuzosin may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Aliskiren	The risk or severity of adverse effects can be increased when Doxazosin is combined with Aliskiren.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Doxazosin.	Approved, Investigational
Alprenolol	Alprenolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved, Withdrawn
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Doxazosin.	Approved, Investigational
Amibegron	Doxazosin may decrease the vasoconstricting activities of SR 58611.	Investigational
Amifostine	Doxazosin may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Doxazosin is combined with Amiloride.	Approved
Amiodarone	The metabolism of Doxazosin can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Doxazosin.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Doxazosin.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Doxazosin.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Doxazosin is combined with Amphotericin B.	Approved, Investigational
Amrinone	Doxazosin may increase the hypotensive activities of Amrinone.	Approved
Amyl Nitrite	The risk or severity of adverse effects can be increased when Doxazosin is combined with Amyl Nitrite.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Doxazosin.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Apraclonidine.	Approved
Arbutamine	Doxazosin may decrease the vasoconstricting activities of Arbutamine.	Approved
Arformoterol	Doxazosin may decrease the vasoconstricting activities of Arformoterol.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Armodafinil	The metabolism of Doxazosin can be decreased when combined with Armodafinil.	Approved, Investigational
Arotinolol	Arotinolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Arsenic trioxide	The serum concentration of Arsenic trioxide can be increased when it is combined with Doxazosin.	Approved, Investigational
Artemether	The metabolism of Doxazosin can be decreased when combined with Artemether.	Approved
Atazanavir	The serum concentration of Atazanavir can be increased when it is combined with Doxazosin.	Approved, Investigational
Atenolol	Atenolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Atomoxetine	The metabolism of Doxazosin can be decreased when combined with Atomoxetine.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Doxazosin.	Approved, Investigational
Azelnidipine	Doxazosin may increase the hypotensive activities of Azelnidipine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Doxazosin is combined with Azilsartan medoxomil.	Approved
Azimilide	Doxazosin may increase the hypotensive activities of Azimilide.	Investigational
Barbexaclone	Barbexaclone may increase the hypotensive activities of Doxazosin.	Experimental
Barbital	Barbital may increase the hypotensive activities of Doxazosin.	Illicit
Barnidipine	Doxazosin may increase the hypotensive activities of Barnidipine.	Approved
Befunolol	Befunolol may increase the orthostatic hypotensive activities of Doxazosin.	Experimental
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Doxazosin.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Doxazosin.	Approved
Benidipine	Doxazosin may increase the hypotensive activities of Benidipine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Doxazosin.	Withdrawn
Bepridil	Doxazosin may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Betaxolol	Betaxolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Bethanidine	Bethanidine may increase the hypotensive activities of Doxazosin.	Approved
Bevantolol	Bevantolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Bimatoprost	Doxazosin may increase the hypotensive activities of Bimatoprost.	Approved, Investigational
Bisoprolol	Bisoprolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Bitolterol	Doxazosin may decrease the vasoconstricting activities of Bitolterol.	Withdrawn
Boceprevir	The serum concentration of Doxazosin can be increased when it is combined with Boceprevir.	Approved, Investigational
Bopindolol	Bopindolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Bortezomib	The metabolism of Doxazosin can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	Bosentan may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Doxazosin.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.	Approved
Bretylium	The risk or severity of adverse effects can be increased when Doxazosin is combined with Bretylium.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Doxazosin.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Doxazosin.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Doxazosin.	Approved, Investigational
Bufuralol	Bufuralol may increase the orthostatic hypotensive activities of Doxazosin.	Experimental, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Bupivacaine.	Approved, Investigational
Bupranolol	Bupranolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Bupropion	The metabolism of Doxazosin can be decreased when combined with Bupropion.	Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Doxazosin.	Approved
Caffeine	The serum concentration of Caffeine can be increased when it is combined with Doxazosin.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Doxazosin.	Experimental
Canagliflozin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Candesartan.	Approved
Candoxatril	Doxazosin may increase the hypotensive activities of Candoxatril.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Doxazosin is combined with Captopril.	Approved
Carbamazepine	The metabolism of Doxazosin can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Carbetocin.	Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Doxazosin.	Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Doxazosin.	Withdrawn
Carteolol	Carteolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Carvedilol	Doxazosin may increase the antihypertensive activities of Carvedilol.	Approved, Investigational
Celecoxib	The metabolism of Doxazosin can be decreased when combined with Celecoxib.	Approved, Investigational
Celiprolol	Celiprolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved, Investigational
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Doxazosin.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Doxazosin.	Withdrawn
Chloramphenicol	The metabolism of Doxazosin can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chloroquine	The metabolism of Doxazosin can be decreased when combined with Chloroquine.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Chlorothiazide.	Approved, Vet Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Doxazosin.	Approved
Cholecalciferol	The metabolism of Doxazosin can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cilazapril	The risk or severity of adverse effects can be increased when Doxazosin is combined with Cilazapril.	Approved
Cilnidipine	Doxazosin may increase the hypotensive activities of Cilnidipine.	Approved
Cimetidine	The serum concentration of Cimetidine can be increased when it is combined with Doxazosin.	Approved
Cinacalcet	The metabolism of Doxazosin can be decreased when combined with Cinacalcet.	Approved
Cinnarizine	Doxazosin may increase the hypotensive activities of Cinnarizine.	Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be increased when it is combined with Doxazosin.	Approved, Investigational
Cirazoline	Doxazosin may decrease the vasoconstricting activities of Cirazoline.	Experimental
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Doxazosin.	Approved
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Doxazosin.	Approved
Clarithromycin	The serum concentration of Clarithromycin can be increased when it is combined with Doxazosin.	Approved
Clemastine	The metabolism of Doxazosin can be decreased when combined with Clemastine.	Approved
Clenbuterol	Doxazosin may decrease the vasoconstricting activities of Clenbuterol.	Approved, Vet Approved
Clevidipine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Clevidipine.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Doxazosin.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Clofarabine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Doxazosin.	Approved, Investigational
Clomipramine	The metabolism of Doxazosin can be decreased when combined with Clomipramine.	Approved, Vet Approved
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Doxazosin.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be increased when it is combined with Doxazosin.	Approved, Nutraceutical
Clotrimazole	The metabolism of Doxazosin can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Clozapine can be increased when it is combined with Doxazosin.	Approved
Cobicistat	The serum concentration of Doxazosin can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Doxazosin.	Approved
Cocaine	The metabolism of Doxazosin can be decreased when combined with Cocaine.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Doxazosin.	Approved
Conivaptan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Doxazosin.	Approved
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Doxazosin.	Approved
Cryptenamine	Doxazosin may increase the hypotensive activities of Cryptenamine.	Approved
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Doxazosin.	Approved, Investigational, Vet Approved
Cyclothiazide	Doxazosin may increase the hypotensive activities of Cyclothiazide.	Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxazosin.	Approved
Dabrafenib	The serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Doxazosin.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Doxazosin.	Investigational
Darifenacin	The metabolism of Doxazosin can be decreased when combined with Darifenacin.	Approved, Investigational
Darodipine	Doxazosin may increase the hypotensive activities of Darodipine.	Experimental
Darunavir	The serum concentration of Doxazosin can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Doxazosin.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be increased when it is combined with Doxazosin.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Doxazosin.	Approved
Delavirdine	The metabolism of Doxazosin can be decreased when combined with Delavirdine.	Approved
Deserpidine	Doxazosin may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Doxazosin is combined with Desflurane.	Approved
Desipramine	The metabolism of Doxazosin can be decreased when combined with Desipramine.	Approved
Dexamethasone	The serum concentration of Dexamethasone can be increased when it is combined with Doxazosin.	Approved, Investigational, Vet Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Dexmedetomidine.	Approved, Vet Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Doxazosin.	Approved, Illicit, Vet Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Doxazosin.	Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Diclofenamide.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Doxazosin.	Approved
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Doxazosin.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Doxazosin.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Doxazosin.	Illicit
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Doxazosin.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.	Approved
Diphenhydramine	The metabolism of Doxazosin can be decreased when combined with Diphenhydramine.	Approved
Dipivefrin	Doxazosin may decrease the vasoconstricting activities of Dipivefrin.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Doxazosin is combined with Dipyridamole.	Approved
Dobutamine	Doxazosin may decrease the vasoconstricting activities of Dobutamine.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Doxazosin.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Doxazosin.	Approved, Investigational, Vet Approved
Dorzolamide	Doxazosin may increase the hypotensive activities of Dorzolamide.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Doxazosin.	Approved, Investigational
Dronedarone	The metabolism of Doxazosin can be decreased when combined with Dronedarone.	Approved
Droxidopa	Doxazosin may decrease the vasoconstricting activities of Droxidopa.	Approved, Investigational
Duloxetine	Doxazosin may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Doxazosin.	Approved
Efavirenz	The metabolism of Doxazosin can be decreased when combined with Efavirenz.	Approved, Investigational
Efonidipine	Doxazosin may increase the hypotensive activities of Efonidipine.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Doxazosin.	Approved, Investigational
Eliglustat	The metabolism of Doxazosin can be decreased when combined with Eliglustat.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Doxazosin.	Approved, Vet Approved
Enalaprilat	Doxazosin may increase the hypotensive activities of Enalaprilat.	Approved
Eperisone	Doxazosin may increase the hypotensive activities of Eperisone.	Approved, Investigational
Ephedrine	Doxazosin may decrease the vasoconstricting activities of Ephedrine.	Approved
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Doxazosin.	Approved, Investigational
Epinephrine	Doxazosin may decrease the vasoconstricting activities of Epinephrine.	Approved, Vet Approved
Eplerenone	The risk or severity of adverse effects can be increased when Doxazosin is combined with Eplerenone.	Approved
Epoprostenol	Doxazosin may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Eprosartan.	Approved
Ergotamine	Doxazosin may decrease the vasoconstricting activities of Ergotamine.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Doxazosin.	Approved, Investigational
Erythromycin	The serum concentration of Erythromycin can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Eslicarbazepine acetate	The metabolism of Doxazosin can be decreased when combined with Eslicarbazepine acetate.	Approved
Esmolol	Esmolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Esomeprazole	The metabolism of Doxazosin can be decreased when combined with Esomeprazole.	Approved, Investigational
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Doxazosin.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be increased when it is combined with Doxazosin.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxazosin.	Approved
Etilefrine	Doxazosin may decrease the vasoconstricting activities of Etilefrine.	Withdrawn
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Doxazosin.	Approved
Etravirine	The metabolism of Doxazosin can be decreased when combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Doxazosin.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Doxazosin.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Felodipine.	Approved, Investigational
Fendiline	Doxazosin may increase the hypotensive activities of Fendiline.	Withdrawn
Fenoldopam	Doxazosin may increase the hypotensive activities of Fenoldopam.	Approved
Fenoterol	Doxazosin may decrease the vasoconstricting activities of Fenoterol.	Approved
Fesoterodine	The serum concentration of Fesoterodine can be increased when it is combined with Doxazosin.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Doxazosin.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Doxazosin.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Fimasartan.	Approved
Fluconazole	The metabolism of Doxazosin can be decreased when combined with Fluconazole.	Approved
Flunarizine	Doxazosin may increase the hypotensive activities of Flunarizine.	Approved
Fluoxetine	The metabolism of Doxazosin can be decreased when combined with Fluoxetine.	Approved, Vet Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Doxazosin.	Approved
Fluvoxamine	The metabolism of Doxazosin can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formoterol	Doxazosin may decrease the vasoconstricting activities of Formoterol.	Approved, Investigational
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Doxazosin.	Approved
Fosphenytoin	The metabolism of Doxazosin can be increased when combined with Fosphenytoin.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Doxazosin.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Furosemide.	Approved, Vet Approved
Gabapentin	Doxazosin may increase the hypotensive activities of Gabapentin.	Approved, Investigational
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Doxazosin.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Doxazosin.	Approved
Gemfibrozil	The metabolism of Doxazosin can be decreased when combined with Gemfibrozil.	Approved
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Doxazosin.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Doxazosin.	Withdrawn
Guanabenz	Doxazosin may increase the hypotensive activities of Guanabenz.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Doxazosin.	Approved
Guanethidine	Doxazosin may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Guanfacine.	Approved, Investigational
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Doxazosin.	Approved
Halothane	The risk or severity of adverse effects can be increased when Doxazosin is combined with Halothane.	Approved, Vet Approved
Hexamethonium	Doxazosin may increase the hypotensive activities of Hexamethonium.	Experimental
Hexobarbital	Hexobarbital may increase the hypotensive activities of Doxazosin.	Approved
Hexoprenaline	Doxazosin may decrease the vasoconstricting activities of Hexoprenaline.	Approved, Withdrawn
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Doxazosin.	Approved
Hydralazine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocortisone	The serum concentration of Hydrocortisone can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Hydroflumethiazide	Doxazosin may increase the hypotensive activities of Hydroflumethiazide.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Doxazosin.	Approved
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Doxazosin.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Doxazosin.	Approved
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Doxazosin.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Doxazosin.	Approved
Indapamide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Indapamide.	Approved
Indenolol	Indenolol may increase the orthostatic hypotensive activities of Doxazosin.	Withdrawn
Indinavir	The serum concentration of Indinavir can be increased when it is combined with Doxazosin.	Approved
Indomethacin	The serum concentration of Indomethacin can be increased when it is combined with Doxazosin.	Approved, Investigational
Indoramin	Doxazosin may increase the antihypertensive activities of Indoramin.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Doxazosin.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Doxazosin.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Irbesartan.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Doxazosin.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Doxazosin.	Approved
Isoetarine	Doxazosin may decrease the vasoconstricting activities of Isoetarine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Doxazosin is combined with Isoflurane.	Approved, Vet Approved
Isoniazid	The metabolism of Doxazosin can be decreased when combined with Isoniazid.	Approved
Isoprenaline	Doxazosin may decrease the vasoconstricting activities of Isoprenaline.	Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Dinitrate.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Mononitrate.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Doxazosin.	Approved
Ivermectin	The serum concentration of Ivermectin can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Doxazosin.	Approved
Ketoconazole	The serum concentration of Ketoconazole can be increased when it is combined with Doxazosin.	Approved, Investigational
Labetalol	Doxazosin may increase the antihypertensive activities of Labetalol.	Approved
Lacidipine	Doxazosin may increase the hypotensive activities of Lacidipine.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Doxazosin.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Doxazosin.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be increased when it is combined with Doxazosin.	Approved, Investigational
Latanoprost	Doxazosin may increase the hypotensive activities of Latanoprost.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Doxazosin.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Doxazosin.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Doxazosin.	Approved
Lercanidipine	Lercanidipine may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Doxazosin.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Doxazosin is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Levobupivacaine.	Approved
Levodopa	Doxazosin may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be increased when it is combined with Doxazosin.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Doxazosin.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Levosimendan.	Approved, Investigational
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Doxazosin.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Doxazosin is combined with Lisinopril.	Approved, Investigational
Lofexidine	Doxazosin may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Doxazosin.	Approved
Lopinavir	The metabolism of Doxazosin can be decreased when combined with Lopinavir.	Approved
Lorcaserin	The metabolism of Doxazosin can be decreased when combined with Lorcaserin.	Approved
Losartan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Losartan.	Approved
Luliconazole	The serum concentration of Doxazosin can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Doxazosin can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The metabolism of Doxazosin can be decreased when combined with Lumefantrine.	Approved
Macitentan	Doxazosin may increase the hypotensive activities of Macitentan.	Approved
Magnesium Sulfate	Doxazosin may increase the hypotensive activities of Magnesium Sulfate.	Approved, Vet Approved
Manidipine	Doxazosin may increase the hypotensive activities of Manidipine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Doxazosin.	Withdrawn
Mecamylamine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Mecamylamine.	Approved
Mephentermine	Doxazosin may decrease the vasoconstricting activities of Mephentermine.	Approved
Metaraminol	Doxazosin may decrease the vasoconstricting activities of Metaraminol.	Approved, Investigational
Methadone	The metabolism of Doxazosin can be decreased when combined with Methadone.	Approved
Methazolamide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Methazolamide.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Doxazosin.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Doxazosin.	Approved
Methotrimeprazine	The metabolism of Doxazosin can be decreased when combined with Methotrimeprazine.	Approved
Methoxamine	Doxazosin may decrease the vasoconstricting activities of Methoxamine.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Doxazosin is combined with Methyldopa.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Doxazosin.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Doxazosin.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Doxazosin.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Metipranolol	The risk or severity of adverse effects can be increased when Doxazosin is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Doxazosin.	Approved
Metoprolol	Metoprolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved, Investigational
Metyrosine	Doxazosin may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	Doxazosin may increase the hypotensive activities of Mibefradil.	Withdrawn
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Doxazosin.	Approved, Illicit
Midodrine	Doxazosin may decrease the vasoconstricting activities of Midodrine.	Approved
Minaprine	Minaprine may increase the hypotensive activities of Doxazosin.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Doxazosin.	Approved
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Doxazosin.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Doxazosin.	Approved, Investigational
Moclobemide	The metabolism of Doxazosin can be decreased when combined with Moclobemide.	Approved
Modafinil	The metabolism of Doxazosin can be decreased when combined with Modafinil.	Approved, Investigational
Moexipril	The risk or severity of adverse effects can be increased when Doxazosin is combined with Moexipril.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Doxazosin.	Approved
Morphine	The serum concentration of Morphine can be increased when it is combined with Doxazosin.	Approved, Investigational
Moxonidine	Doxazosin may increase the hypotensive activities of Moxonidine.	Approved
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxazosin.	Approved, Investigational
Nabilone	The risk or severity of adverse effects can be increased when Doxazosin is combined with Nabilone.	Approved, Investigational
Nadolol	Nadolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Doxazosin.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Naphazoline	Doxazosin may decrease the vasoconstricting activities of Naphazoline.	Approved
Nebivolol	The risk or severity of adverse effects can be increased when Doxazosin is combined with Nebivolol.	Approved, Investigational
Nelfinavir	The serum concentration of Nelfinavir can be increased when it is combined with Doxazosin.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Nesiritide.	Approved, Investigational
Nevirapine	The metabolism of Doxazosin can be decreased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the hypotensive activities of Doxazosin.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Nicardipine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Doxazosin.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Nifedipine.	Approved
Niguldipine	Doxazosin may increase the hypotensive activities of Niguldipine.	Experimental
Nilotinib	The serum concentration of Nilotinib can be increased when it is combined with Doxazosin.	Approved, Investigational
Niludipine	Doxazosin may increase the hypotensive activities of Niludipine.	Experimental
Nilvadipine	Doxazosin may increase the hypotensive activities of Nilvadipine.	Approved
Nimesulide	Doxazosin may increase the hypotensive activities of Nimesulide.	Approved, Withdrawn
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Doxazosin.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Doxazosin.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Doxazosin.	Approved
Nitrendipine	Doxazosin may increase the hypotensive activities of Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Nitric Oxide.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Doxazosin.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Doxazosin.	Approved
Norepinephrine	Doxazosin may decrease the vasoconstricting activities of Norepinephrine.	Approved
Obinutuzumab	Doxazosin may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Doxazosin.	Withdrawn
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Doxazosin.	Approved, Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Doxazosin.	Approved, Investigational
Olodaterol	Doxazosin may decrease the vasoconstricting activities of Olodaterol.	Approved
Omapatrilat	Doxazosin may increase the hypotensive activities of Omapatrilat.	Investigational
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Doxazosin.	Approved
Omeprazole	The metabolism of Doxazosin can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Orciprenaline	Doxazosin may decrease the vasoconstricting activities of Orciprenaline.	Approved
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Doxazosin.	Approved
Oxprenolol	Oxprenolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Oxymetazoline	Doxazosin may decrease the vasoconstricting activities of Oxymetazoline.	Approved
Paclitaxel	The serum concentration of Paclitaxel can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Panobinostat	The serum concentration of Doxazosin can be increased when it is combined with Panobinostat.	Approved, Investigational
Pantoprazole	The metabolism of Doxazosin can be decreased when combined with Pantoprazole.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Doxazosin.	Approved
Paroxetine	The metabolism of Doxazosin can be decreased when combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Doxazosin.	Approved
Peginterferon alfa-2b	The serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Penbutolol	Penbutolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved, Investigational
Pentobarbital	Pentobarbital may increase the hypotensive activities of Doxazosin.	Approved, Vet Approved
Pentolinium	Doxazosin may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Perhexiline	Doxazosin may increase the hypotensive activities of Perhexiline.	Approved
Perindopril	The risk or severity of adverse effects can be increased when Doxazosin is combined with Perindopril.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Doxazosin.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Doxazosin.	Withdrawn
Phenobarbital	The serum concentration of Phenobarbital can be increased when it is combined with Doxazosin.	Approved
Phenoxybenzamine	Doxazosin may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Doxazosin.	Withdrawn
Phentolamine	Doxazosin may increase the hypotensive activities of Phentolamine.	Approved
Phenylephrine	Doxazosin may decrease the vasoconstricting activities of Phenylephrine.	Approved
Phenylpropanolamine	Doxazosin may decrease the vasoconstricting activities of Phenylpropanolamine.	Approved, Vet Approved, Withdrawn
Phenytoin	The metabolism of Doxazosin can be increased when combined with Phenytoin.	Approved, Vet Approved
Pinaverium	Doxazosin may increase the hypotensive activities of Pinaverium.	Approved
Pindolol	Pindolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Doxazosin is combined with Pipamperone.	Approved
Pirbuterol	Doxazosin may decrease the vasoconstricting activities of Pirbuterol.	Approved
Pirlindole	Pirlindole may increase the hypotensive activities of Doxazosin.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Doxazosin.	Approved
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Doxazosin.	Withdrawn
Polythiazide	Doxazosin may increase the hypotensive activities of Polythiazide.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Doxazosin.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Doxazosin.	Approved
Practolol	Practolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Doxazosin is combined with Pramipexole.	Approved, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Doxazosin.	Approved
Prazosin	Prazosin may increase the antihypertensive activities of Doxazosin.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Pregabalin	Doxazosin may increase the hypotensive activities of Pregabalin.	Approved, Illicit, Investigational
Prenylamine	Doxazosin may increase the hypotensive activities of Prenylamine.	Withdrawn
Primidone	Primidone may increase the hypotensive activities of Doxazosin.	Approved, Vet Approved
Procaterol	Doxazosin may decrease the vasoconstricting activities of Procaterol.	Approved
Progesterone	The serum concentration of Progesterone can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Promazine	The metabolism of Doxazosin can be decreased when combined with Promazine.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Doxazosin is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	Propranolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved, Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Doxazosin.	Approved
Pseudoephedrine	Doxazosin may decrease the vasoconstricting activities of Pseudoephedrine.	Approved
Quetiapine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Doxazosin is combined with Quinapril.	Approved, Investigational
Quinidine	The metabolism of Doxazosin can be decreased when combined with Quinidine.	Approved
Quinine	Quinine may increase the hypotensive activities of Doxazosin.	Approved
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Doxazosin.	Approved
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Doxazosin.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Doxazosin.	Approved, Investigational
Rasagiline	Rasagiline may increase the hypotensive activities of Doxazosin.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Doxazosin is combined with Remifentanil.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Doxazosin.	Approved
Rescinnamine	Doxazosin may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Doxazosin.	Approved
Rifampicin	The metabolism of Doxazosin can be increased when combined with Rifampicin.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Doxazosin.	Approved, Investigational
Riociguat	The risk or severity of adverse effects can be increased when Doxazosin is combined with Riociguat.	Approved
Risedronate	Doxazosin may increase the hypotensive activities of Risedronate.	Approved, Investigational
Risperidone	Doxazosin may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritodrine	Doxazosin may decrease the vasoconstricting activities of Ritodrine.	Approved
Ritonavir	The metabolism of Doxazosin can be decreased when combined with Ritonavir.	Approved, Investigational
Rituximab	Doxazosin may increase the hypotensive activities of Rituximab.	Approved
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Doxazosin.	Approved
Rolapitant	The metabolism of Doxazosin can be decreased when combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Doxazosin.	Approved, Investigational
Ropinirole	The metabolism of Doxazosin can be decreased when combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Ropivacaine.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Rotigotine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Doxazosin is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Doxazosin.	Withdrawn
Salbutamol	Doxazosin may decrease the vasoconstricting activities of Salbutamol.	Approved, Vet Approved
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Doxazosin.	Approved, Vet Approved
Salmeterol	Doxazosin may decrease the vasoconstricting activities of Salmeterol.	Approved
Saprisartan	Doxazosin may increase the hypotensive activities of Saprisartan.	Experimental
Saquinavir	The serum concentration of Saquinavir can be increased when it is combined with Doxazosin.	Approved, Investigational
Secobarbital	Secobarbital may increase the hypotensive activities of Doxazosin.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Doxazosin.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Doxazosin.	Approved
Sertraline	The metabolism of Doxazosin can be decreased when combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Doxazosin is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Doxazosin.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Doxazosin.	Approved
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Doxazosin.	Approved, Investigational
Sitaxentan	Doxazosin may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium Nitrite	The risk or severity of adverse effects can be increased when Doxazosin is combined with Sodium Nitrite.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Doxazosin.	Approved
Solabegron	Doxazosin may decrease the vasoconstricting activities of Solabegron.	Investigational
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Doxazosin.	Approved, Investigational
Sotalol	Sotalol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Doxazosin.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Doxazosin.	Experimental
Spirapril	Doxazosin may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Doxazosin.	Approved
Stiripentol	The metabolism of Doxazosin can be decreased when combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Doxazosin is combined with Streptokinase.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Doxazosin is combined with Sufentanil.	Approved, Investigational
Synephrine	Doxazosin may decrease the vasoconstricting activities of Synephrine.	Experimental
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Doxazosin.	Approved, Investigational
Tadalafil	Tadalafil may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Doxazosin.	Approved
Tamsulosin	Doxazosin may increase the antihypertensive activities of Tamsulosin.	Approved, Investigational
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Doxazosin.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Doxazosin.	Approved
Telaprevir	The serum concentration of Telaprevir can be increased when it is combined with Doxazosin.	Withdrawn
Telmisartan	The risk or severity of adverse effects can be increased when Doxazosin is combined with Telmisartan.	Approved, Investigational
Temocapril	Doxazosin may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Doxazosin.	Approved
Terazosin	Doxazosin may increase the antihypertensive activities of Terazosin.	Approved
Terbinafine	The metabolism of Doxazosin can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Terbutaline	Doxazosin may decrease the vasoconstricting activities of Terbutaline.	Approved
Terlipressin	Doxazosin may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Doxazosin is combined with Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	Thiamylal may increase the hypotensive activities of Doxazosin.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Doxazosin.	Approved, Vet Approved
Thioridazine	The metabolism of Doxazosin can be decreased when combined with Thioridazine.	Withdrawn
Tibolone	Doxazosin may increase the hypotensive activities of Tibolone.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Doxazosin.	Approved
Ticlopidine	The metabolism of Doxazosin can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	Doxazosin may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	Timolol may increase the orthostatic hypotensive activities of Doxazosin.	Approved
Tipranavir	The metabolism of Doxazosin can be decreased when combined with Tipranavir.	Approved, Investigational
Tizanidine	The risk or severity of adverse effects can be increased when Doxazosin is combined with Tizanidine.	Approved
Tolazoline	Doxazosin may increase the hypotensive activities of Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Doxazosin is combined with Tolcapone.	Approved, Withdrawn
Tolfenamic Acid	Doxazosin may increase the hypotensive activities of Tolfenamic Acid.	Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Doxazosin.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Doxazosin.	Approved
Topiramate	The metabolism of Doxazosin can be decreased when combined with Topiramate.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Doxazosin.	Approved, Investigational
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Doxazosin.	Approved
Toremifene	The serum concentration of Toremifene can be increased when it is combined with Doxazosin.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Doxazosin.	Approved
Tranilast	Doxazosin may increase the hypotensive activities of Tranilast.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Doxazosin.	Experimental
Tranylcypromine	The metabolism of Doxazosin can be decreased when combined with Tranylcypromine.	Approved
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Doxazosin.	Approved
Travoprost	Travoprost may increase the hypotensive activities of Doxazosin.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Doxazosin.	Approved
Trichlormethiazide	Doxazosin may increase the hypotensive activities of Trichlormethiazide.	Approved, Vet Approved
Trimazosin	Doxazosin may increase the antihypertensive activities of Trimazosin.	Experimental
Trimethaphan	Doxazosin may increase the hypotensive activities of Trimethaphan.	Approved
Udenafil	Udenafil may increase the hypotensive activities of Doxazosin.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Doxazosin.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Doxazosin.	Approved
Unoprostone	Doxazosin may increase the hypotensive activities of Unoprostone.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Doxazosin.	Approved, Investigational
Vardenafil	Vardenafil may increase the hypotensive activities of Doxazosin.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Doxazosin.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Doxazosin.	Approved
Venlafaxine	The serum concentration of Venlafaxine can be increased when it is combined with Doxazosin.	Approved
Verapamil	The risk or severity of adverse effects can be increased when Doxazosin is combined with Verapamil.	Approved
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Doxazosin.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Doxazosin.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Doxazosin.	Approved
Voriconazole	The metabolism of Doxazosin can be decreased when combined with Voriconazole.	Approved, Investigational
Xylometazoline	Doxazosin may increase the hypotensive activities of Xylometazoline.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Doxazosin.	Approved, Vet Approved
Ziconotide	Doxazosin may increase the hypotensive activities of Ziconotide.	Approved
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Doxazosin.	Approved
Ziprasidone	The metabolism of Doxazosin can be decreased when combined with Ziprasidone.	Approved

Food Interactions

Avoid alcohol.
Avoid natural licorice.
Take without regard to meals.

References

Synthesis Reference

K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, "Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines." U.S. Patent US5919931, issued September, 1986.

US5919931

General References

Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14728
KEGG Drug	D07874
KEGG Compound	C06970
PubChem Compound	3157
PubChem Substance	46506825
ChemSpider	3045
BindingDB	86731
ChEBI	4708
ChEMBL	CHEMBL707
Therapeutic Targets Database	DAP000381
PharmGKB	PA449407
Drug Product Database	11258
RxList	http://www.rxlist.com/cgi/generic/doxazo.htm
Drugs.com	http://www.drugs.com/doxazosin.html
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/car1069.shtml
Wikipedia	Doxazosin

ATC Codes

C02CA04

AHFS Codes

24:20.00

PDB Entries

Not Available

FDA label

Download (511 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Cocaine Abuse / Dependence, Cocaine / Substance Abuse	1
1	Completed	Not Available	Substance-Related Disorders	1
1	Completed	Basic Science	Amphetamine-Related Disorders / Moods Disorders / Substance-Related Disorders	1
1	Completed	Treatment	Dependence, Cocaine	1
1	Completed	Treatment	Erectile Dysfunction (ED)	1
1	Completed	Treatment	Healthy Volunteers	1
1	Recruiting	Treatment	Dependence, Cocaine	1
1	Recruiting	Treatment	PTSD	1
1, 2	Completed	Treatment	Methamphetamine or Cocaine Dependence	1
1, 2	Not Yet Recruiting	Treatment	Alcohol Use Disorder (AUD) / PTSD	1
2	Active Not Recruiting	Treatment	Smoking	1
2	Completed	Diagnostic	Dependence, Cocaine	1
2	Completed	Treatment	Alcohol Dependence / Feeling Anxious	1
2	Completed	Treatment	Benign Prostatic Hyperplasia (BPH)	1
2	Completed	Treatment	Cardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases	1
2	Not Yet Recruiting	Treatment	Alcoholism	1
2	Recruiting	Treatment	Alcohol Use Disorders (AUD) / Posttraumatic Stress Disorders / PTSD	1
2	Recruiting	Treatment	Dependence, Cocaine	1
2, 3	Recruiting	Treatment	Hypertensive	1
3	Completed	Prevention	Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / Hypercholesterolaemia / Hypertensive / Myocardial Infarction (MI) / Myocardial Ischemia	1
3	Completed	Treatment	Prostatic Hyperplasia / Prostatic Hypertrophy, Benign	1
3	Recruiting	Treatment	Paraganglioma / Pheochromocytomas	1
3	Unknown Status	Treatment	Renal Stones	1
4	Active Not Recruiting	Treatment	Hypertension, Resistant to Conventional Therapy	1
4	Completed	Basic Science	Idiopathic Dilated Cardiomyopathy	1
4	Completed	Treatment	High Blood Pressure	1
4	Completed	Treatment	Hypertensive	4
4	Completed	Treatment	Stress Disorders, Post-Traumatic	1
4	Recruiting	Treatment	Cardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes	1
4	Recruiting	Treatment	Pheochromocytomas	1
4	Unknown Status	Prevention	Diabetic Nephropathies	1
4	Withdrawn	Treatment	Benign Prostatic Hyperplasia (BPH)	1
Not Available	Completed	Basic Science	Benign Prostatic Hyperplasia (BPH)	1
Not Available	Terminated	Treatment	Hypertensive / Microvascular Angina	1
Not Available	Terminated	Treatment	Prostatic Hyperplasia / Urinary Retention	1

Pharmacoeconomics

Manufacturers

Pfizer inc
Pfizer laboratories div pfizer inc
Actavis elizabeth llc
Apotex inc
Dava pharmaceuticals inc
Genpharm inc
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Kv pharmaceutical co
Mylan pharmaceuticals inc
Pliva inc
Sandoz inc
Teva pharmaceuticals usa inc
Watson laboratories inc

Packagers

Actavis Group
Advanced Pharmaceutical Services Inc.
Amerisource Health Services Corp.
Apotex Inc.
A-S Medication Solutions LLC
Cardinal Health
DAVA Pharmaceuticals
Dept Health Central Pharmacy
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
General Injectables and Vaccines Inc.
Golden State Medical Supply Inc.
Heartland Repack Services LLC
International Laboratories Inc.
Ivax Pharmaceuticals
Legacy Pharmaceuticals Packaging LLC
Major Pharmaceuticals
Merrell Pharmaceuticals Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Novopharm Ltd.
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
Patheon Inc.
Pfizer Inc.
Pharmaceutical Utilization Management Program VA Inc.
Physicians Total Care Inc.
Pliva Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Redpharm Drug
Remedy Repack
Sandhills Packaging Inc.
Southwood Pharmaceuticals
Stat Rx Usa
Teva Pharmaceutical Industries Ltd.
Torpharm Inc.
Tya Pharmaceuticals
UDL Laboratories
US Pharmaceutical Group
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet, multilayer, extended release	Oral	4 mg/1
Tablet, multilayer, extended release	Oral	8 mg/1
Tablet	Oral	1 mg
Kit; tablet	Oral
Tablet	Oral	2 mg
Tablet	Oral	4 mg
Tablet	Oral	1 mg/1
Tablet	Oral	2 mg/1
Tablet	Oral	4 mg/1
Tablet	Oral	8 mg/1

Prices

Unit description	Cost	Unit
Cardura XL 4 mg 24 Hour tablet	2.22USD	tablet
Cardura xl 8 mg tablet	2.04USD	tablet
Cardura xl 4 mg tablet	1.94USD	tablet
Cardura 8 mg tablet	1.93USD	tablet
Cardura 4 mg tablet	1.89USD	tablet
Cardura 2 mg tablet	1.81USD	tablet
Cardura 1 mg tablet	1.72USD	tablet
Doxazosin mesylate 8 mg tablet	1.04USD	tablet
Cardura 4 mg Tablet	1.0USD	tablet
Doxazosin mesylate 4 mg tablet	0.99USD	tablet
Doxazosin mesylate 1 mg tablet	0.94USD	tablet
Doxazosin mesylate 2 mg tablet	0.94USD	tablet
Cardura 2 mg Tablet	0.77USD	tablet
Cardura 1 mg Tablet	0.64USD	tablet
Apo-Doxazosin 4 mg Tablet	0.56USD	tablet
Mylan-Doxazosin 4 mg Tablet	0.56USD	tablet
Novo-Doxazosin 4 mg Tablet	0.56USD	tablet
Pms-Doxazosin 4 mg Tablet	0.56USD	tablet
Apo-Doxazosin 2 mg Tablet	0.43USD	tablet
Mylan-Doxazosin 2 mg Tablet	0.43USD	tablet
Novo-Doxazosin 2 mg Tablet	0.43USD	tablet
Pms-Doxazosin 2 mg Tablet	0.43USD	tablet
Apo-Doxazosin 1 mg Tablet	0.36USD	tablet
Mylan-Doxazosin 1 mg Tablet	0.36USD	tablet
Novo-Doxazosin 1 mg Tablet	0.36USD	tablet
Pms-Doxazosin 1 mg Tablet	0.36USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	289-290 °C	Not Available
water solubility	24 mg/L	Not Available
logP	2.1	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.79 mg/mL	ALOGPS
logP	2.53	ALOGPS
logP	2.14	ChemAxon
logS	-2.8	ALOGPS
pKa (Strongest Acidic)	12.67	ChemAxon
pKa (Strongest Basic)	7.24	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	9	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	112.27 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	121.64 m³·mol^-1	ChemAxon
Polarizability	46.63 Å³	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9627
Caco-2 permeable	+	0.7863
P-glycoprotein substrate	Substrate	0.7303
P-glycoprotein inhibitor I	Non-inhibitor	0.7391
P-glycoprotein inhibitor II	Non-inhibitor	0.9528
Renal organic cation transporter	Non-inhibitor	0.6909
CYP450 2C9 substrate	Non-substrate	0.9011
CYP450 2D6 substrate	Non-substrate	0.8195
CYP450 3A4 substrate	Substrate	0.7228
CYP450 1A2 substrate	Non-inhibitor	0.8293
CYP450 2C9 inhibitor	Non-inhibitor	0.9161
CYP450 2D6 inhibitor	Non-inhibitor	0.9533
CYP450 2C19 inhibitor	Non-inhibitor	0.9084
CYP450 3A4 inhibitor	Non-inhibitor	0.8002
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9078
Ames test	Non AMES toxic	0.5648
Carcinogenicity	Non-carcinogens	0.8905
Biodegradation	Not ready biodegradable	0.9854
Rat acute toxicity	2.1954 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8602
hERG inhibition (predictor II)	Inhibitor	0.823

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0udi-0010900000-9601aa919c95799ec009	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0kei-0981100000-a9ee3121ba6832366f8e	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0a4i-0970000000-5261f1bc60ceee4364de	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0a4i-0950000000-f649236044e4e2a5de38	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0a4i-1920000000-86655cc3bb892d757068	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0a4i-1900000000-88bca2ddf2930fa0c468	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0udi-0000900000-449254642300c1324285	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0udi-0002900000-3097c8a3403b52610918	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0006-0079100000-06d36a9b7afe6cf0c6e9	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-000t-1091000000-cbd9b2106818ef5fd2ba	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-001i-1190000000-a1c84b0c3657d8000e35	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-001i-1390000000-e802cb93ca8d6934ee96	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Diazinanes

Sub Class

Piperazines

Direct Parent

N-arylpiperazines

Alternative Parents

Quinazolinamines / Benzo-1,4-dioxanes / Anisoles / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Para dioxins / Imidolactams / Tertiary carboxylic acid amides / Heteroaromatic compounds

Substituents

N-arylpiperazine / Quinazolinamine / Diazanaphthalene / Benzo-1,4-dioxane / Benzodioxane / Quinazoline / Anisole / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

N-arylpiperazine, monocarboxylic acid amide, aromatic amine, quinazolines, benzodioxine, N-acylpiperazine (CHEBI:4708 )

Targets

Details

1. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1A
Uniprot ID:: P35348
Molecular Weight:: 51486.005 Da

References

Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J: Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol. 2004 Oct;82(10):872-8. [PubMed:15573147 ]
Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427 ]
Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264 ]
Ishizuka O, Pandita RK, Mattiasson A, Steers WD, Andersson KE: Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):787-93. [PubMed:9205965 ]
Bae JH, Jung PB, Lee JG: The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int. 2005 Nov;96(7):1131-5. [PubMed:16225542 ]
Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Alpha-1B adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1B
Uniprot ID:: P35368
Molecular Weight:: 56835.375 Da

References

Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]

Details

3. Alpha-1D adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Alpha1-adrenergic receptor activity
Specific Function:: This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:: ADRA1D
Uniprot ID:: P25100
Molecular Weight:: 60462.205 Da

References

Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]

Details

4. Potassium voltage-gated channel subfamily H member 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:: Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:: KCNH2
Uniprot ID:: Q12809
Molecular Weight:: 126653.52 Da

References

Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Details

5. Potassium voltage-gated channel subfamily H member 6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Voltage-gated potassium channel activity
Specific Function:: Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:: KCNH6
Uniprot ID:: Q9H252
Molecular Weight:: 109923.705 Da

References

Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Details

6. Potassium voltage-gated channel subfamily H member 7

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Voltage-gated potassium channel activity
Specific Function:: Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:: KCNH7
Uniprot ID:: Q9NS40
Molecular Weight:: 134998.525 Da

References

Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Enzymes

Details

1. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Molecular Weight:: 55930.545 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

2. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Molecular Weight:: 55768.94 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Details

1. Alpha-1-acid glycoprotein 1

Kind: Protein
Organism: Human
Pharmacological action: no

General Function:: Not Available
Specific Function:: Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:: ORM1
Uniprot ID:: P02763
Molecular Weight:: 23511.38 Da

References

Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]

Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 15:40

Get DrugBank to go!

Structure for DB00590 (Doxazosin)

Targets

References

References

References

References

References

References

Enzymes

References

References

Carriers

References

Transporters

References